BioNTech SE (BNTX) Reports Q3 Loss of EUR0.88/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Boston Scientific discloses cybersecurity incident causing global disruption
- Wall Street ends higher as tech rebounds before Nvidia results
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
BioNTech Announces Third Quarter 2020 Financial Results and Corporate Progress
November 10, 2020 7:15 AM ESTBNT162b2 vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in first interim efficacy analysis from Phase 3 trial Analysis evaluated 94 confirmed cases of COVID-19 in trial participantsStudy enrolled 43,538 participants with 42% having diverse backgrounds and no serious safety concerns have been observed; safety and additional efficacy data continue to be collected Submission for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) planned for soon after required safety milestone is achieved, which is currently expected... More
